Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 8/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29399570 | 1.00 | CA12 (0.45) | CA12CA1CA2CA4CA6 | |
| SCHEMBL28920130 | 0.88 | CA12 (0.39) | CA12CA1CA2CA4CA6 | |
| SCHEMBL30084937 | 0.88 | CA12 (0.39) | CA12CA1CA2CA4CA6 | |
| SCHEMBL30084910 | 0.84 | AR (0.45) | CA12CA1CA2CA4CA6 | |
| SCHEMBL1094827 | 0.84 | CA12 (0.41) | CA12CA1CA2CA4CA6 | |
| SCHEMBL30296403 | 0.84 | KIF11 (0.37) | CA12CA1CA2CA4CA6 | |
| SCHEMBL26095784 | 0.84 | KIF11 (0.37) | CA12CA1CA2CA4CA6 | |
| SCHEMBL22445775 | 0.84 | AR (0.45) | CA12CA1CA2CA4CA6 | |
| SCHEMBL21816639 | 0.84 | AR (0.45) | CA12CA1CA2CA4CA6 | |
| SCHEMBL15797298 | 0.82 | CA12 (0.40) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492188-B2 | 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| US-12479807-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4200292-B1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-13 | — | — | EP | disclosed |
| US-11905248-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230295122-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295122-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4200292-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | Bristol-Myers Squibb Company (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20220235018-A1 | METHODS USING HDAC11 INHIBITORS | Valo Health, LLC | 2022-07-28 | — | — | US | disclosed |
| US-11345672-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-7541362-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| EP-2049481-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SmithKline Beecham Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2021330-A2 | BENZIMIDAZOLE MODULATORS OF VR1 | Janssen Pharmaceutica, N.V. (BE) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007130780-A2 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-08 | — | — | US | disclosed |
| EP-1551811-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Amgen Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004035549-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295122-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | CA12 4119/4885CA1 4639/4885CA2 2114/4885 |
| US-11345672-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | CA12 1912/4885CA1 2041/4885CA2 3469/4885 |
| US-12492188-B2 | 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | TLR9, TLR1, TLR7 | CA12 4119/4885CA1 4639/4885CA2 2114/4885 |
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | VRK1, VRK2, VIL1 | CA12 4775/4885CA1 4688/4885CA2 2509/4885 |
| US-12479807-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | CA12 1912/4885CA1 2041/4885CA2 3469/4885 |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | CA12 2410/4885CA1 2896/4885CA2 790/4885 |
| US-20220235018-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | CA12 1912/4885CA1 2041/4885CA2 3469/4885 |
| US-11905248-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | CA12 3961/4885CA1 1250/4885CA2 86/4885 |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | CA12 4874/4885CA1 4804/4885CA2 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.